Angelini Pharma has completed LIFE-GREENAPI, a European project designed to reduce the environmental impact of active pharmaceutical ingredient production through a combined batch and flow chemistry model.
The project focused on one of pharmaceutical manufacturing’s more difficult sustainability challenges: improving the resource efficiency of API production without compromising quality, reliability, regulatory control, or cost effectiveness. Angelini Pharma coordinated the three-year initiative with support from Leiden University and co-funding from the European Union’s LIFE Programme.
LIFE-GREENAPI was developed around the company’s Angelini Fine Chemicals production activity in Aprilia, Italy. The project applied an integrated flow-batch approach to a high-production-volume API, using life cycle assessment to measure environmental performance and compare the redesigned process with conventional production routes.
Angelini Pharma says the project achieved reductions of 19% to 56% across several environmental indicators, while also supporting a more cost-effective production process. The work combined re-engineered batch processing with flow chemistry, allowing the project team to evaluate which technology performed best at specific synthetic steps rather than treating batch and continuous processing as mutually exclusive choices.
API manufacturing is often resource-intensive. Chemical synthesis can require significant solvent use, water, energy, reagents, cleaning, separation, and waste handling. The environmental footprint is shaped by every stage of the production route, including reaction conditions, solvent volumes, yields, purification steps, waste treatment, and energy demand.
Flow chemistry offers several potential advantages in this context. Reactions can be run in smaller volumes, with improved heat and mass transfer, faster reaction rates, tighter process control, and potentially lower solvent and energy use. Continuous systems can also improve safety where hazardous intermediates, exothermic reactions, or high-pressure conditions are involved. Adoption in pharmaceutical production remains constrained by regulatory validation, equipment design, cleaning, process understanding, and change-control requirements.
The focus on measurable resource reduction reflects the same engineering discipline behind John Crane’s sealing retrofit, which reduced water use in a critical slurry-pumping process. In both cases, environmental gains come from specific process changes, data, equipment choices, and repeatable operating control rather than broad sustainability language.
LIFE-GREENAPI used life cycle assessment to quantify performance. LCA is particularly valuable in chemical and pharmaceutical production because improvements in one area can shift burdens elsewhere. A process that uses less solvent may require more energy. A faster reaction may demand more complex equipment. A lower-waste route may introduce new purification requirements. Measuring the full system helps avoid narrow optimisation.
The project also tested transferability. After work on the initial API, the integrated flow-batch approach was applied to a synthetic step in a second API production process to demonstrate broader applicability. That gives the model greater industrial value, as pharmaceutical manufacturing contains many legacy products made through established routes. A greener process model becomes more useful when it can be adapted across molecules, plants, and production scales.
The regulatory barrier remains substantial. API production sits inside strict quality and compliance systems, and any change to a validated process can require evidence that product quality, impurity profile, stability, safety, and reproducibility remain controlled. Moving from pre-industrial demonstration to full industrial production involves documentation, validation, quality risk assessment, process control, and regulatory confidence.
The economic case is equally important. Sustainability measures that sharply increase cost can struggle to move beyond pilots, particularly for mature products under price pressure. LIFE-GREENAPI’s emphasis on environmental performance and cost effectiveness gives it stronger industrial relevance. Lower solvent use, reduced waste, improved yield, shorter processing time, and better energy efficiency can all support the business case when delivered without weakening compliance or supply reliability.
Pharmaceutical manufacturers face growing pressure to reduce emissions, waste, and resource use across product life cycles. The sector has difficult constraints: quality requirements are non-negotiable, production routes can be complex, and many processes were validated long before current sustainability expectations took shape. LIFE-GREENAPI shows how targeted process redesign can fit within those constraints, using flow chemistry where it offers clear value while retaining batch processing where it remains the better industrial tool.
